In collaboration with the South African Health Products Regulatory Authority (SAHPRA), numerous pharmaceutical companies have recommended that DPYD pre-testing be performed to identify patients at increased risk of severe toxicity due to fluoropyrimidine containing medicines². Both genotyping of the DPYD variants listed above and phenotyping by measurement of blood uracil levels are listed as acceptable methods.
Dihydropyrimidine dehydrogenase (DPYD)